FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2738559968> ?p ?o ?g. }

• W2738559968 endingPage "60" @default.
• W2738559968 startingPage "55" @default.
• W2738559968 abstract "BackgroundRandomized Controlled Trials showed that omalizumab exhibited a good safety and tolerability profile in patients with moderate-to-severe asthma. However, safety data of long-term treatment with omalizumab are scarce. Our aim was to assess the safety of omalizumab in patients under long-term treatment in a real-life setting.MethodsDifficult-to-control asthmatic patients treated with omalizumab up to 9 years were retrospectively evaluated. Mild to severe adverse events any and reasons for discontinuation were recorded.ResultsNinety-one patients (26.4% males, mean age 49.9 ± 14.9 years) were included: mean treatment length, 3.8 ± 2.6 years; mean individual monthly dose, 514.5 ± 345.7 mg (range, 150–1200 mg). A total of 10,472 single injections were given cumulatively to the 91 patients (115 single injections per patients, on average, over a treatment period up to 9 years). Fifty-nine patients (64.8%) were treated for a period of time from 3 to 9 years, 14 of whom from 6 to 9 years. A high proportion of patients who discontinued treatment dropped out within the first year (18, 39.1%), mainly for reasons unrelated to treatment. Six patients (6.6%) discontinued omalizumab for treatment-related adverse events: arthralgia/myalgia (3 patients); urticaria, angioedema (1 patients); metrorrhagia (1 patient); relapsing herpes labialis (1 patient). Four other patients complained of mild adverse events (rhinitis/conjunctivitis, injection site reaction, fatigue, thrombosis) but continued the treatment. Anaphylaxis was not reported.ConclusionsLong-term treatment with omalizumab appears remarkably safe and well tolerated in real-life setting. Prolonged omalizumab treatment for many consecutive years did not increase the risk of side effects, particularly anaphylaxis." @default.
• W2738559968 created "2017-07-31" @default.
• W2738559968 creator A5012066985 @default.
• W2738559968 creator A5014181660 @default.
• W2738559968 creator A5018581935 @default.
• W2738559968 creator A5026141761 @default.
• W2738559968 creator A5026296304 @default.
• W2738559968 creator A5034213384 @default.
• W2738559968 creator A5035411851 @default.
• W2738559968 creator A5038859733 @default.
• W2738559968 creator A5056484495 @default.
• W2738559968 creator A5058464748 @default.
• W2738559968 creator A5060067015 @default.
• W2738559968 creator A5060303060 @default.
• W2738559968 creator A5074258039 @default.
• W2738559968 creator A5089497961 @default.
• W2738559968 date "2017-09-01" @default.
• W2738559968 modified "2023-10-17" @default.
• W2738559968 title "Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study" @default.
• W2738559968 cites W1983832849 @default.
• W2738559968 cites W1986966401 @default.
• W2738559968 cites W2008522421 @default.
• W2738559968 cites W2010946738 @default.
• W2738559968 cites W2017866305 @default.
• W2738559968 cites W2024329120 @default.
• W2738559968 cites W2024939003 @default.
• W2738559968 cites W2029587541 @default.
• W2738559968 cites W2034349740 @default.
• W2738559968 cites W2037071616 @default.
• W2738559968 cites W2040565769 @default.
• W2738559968 cites W2053967304 @default.
• W2738559968 cites W2060015303 @default.
• W2738559968 cites W2060636831 @default.
• W2738559968 cites W2061775758 @default.
• W2738559968 cites W2066531673 @default.
• W2738559968 cites W2084213720 @default.
• W2738559968 cites W2091953276 @default.
• W2738559968 cites W2093655113 @default.
• W2738559968 cites W2099211356 @default.
• W2738559968 cites W2137404654 @default.
• W2738559968 cites W2146852572 @default.
• W2738559968 cites W2149809437 @default.
• W2738559968 cites W2161602728 @default.
• W2738559968 cites W2192072888 @default.
• W2738559968 cites W2519347052 @default.
• W2738559968 doi "https://doi.org/10.1016/j.rmed.2017.07.013" @default.
• W2738559968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29206634" @default.
• W2738559968 hasPublicationYear "2017" @default.
• W2738559968 type Work @default.
• W2738559968 sameAs 2738559968 @default.
• W2738559968 citedByCount "58" @default.
• W2738559968 countsByYear W27385599682017 @default.
• W2738559968 countsByYear W27385599682018 @default.
• W2738559968 countsByYear W27385599682019 @default.
• W2738559968 countsByYear W27385599682020 @default.
• W2738559968 countsByYear W27385599682021 @default.
• W2738559968 countsByYear W27385599682022 @default.
• W2738559968 countsByYear W27385599682023 @default.
• W2738559968 crossrefType "journal-article" @default.
• W2738559968 hasAuthorship W2738559968A5012066985 @default.
• W2738559968 hasAuthorship W2738559968A5014181660 @default.
• W2738559968 hasAuthorship W2738559968A5018581935 @default.
• W2738559968 hasAuthorship W2738559968A5026141761 @default.
• W2738559968 hasAuthorship W2738559968A5026296304 @default.
• W2738559968 hasAuthorship W2738559968A5034213384 @default.
• W2738559968 hasAuthorship W2738559968A5035411851 @default.
• W2738559968 hasAuthorship W2738559968A5038859733 @default.
• W2738559968 hasAuthorship W2738559968A5056484495 @default.
• W2738559968 hasAuthorship W2738559968A5058464748 @default.
• W2738559968 hasAuthorship W2738559968A5060067015 @default.
• W2738559968 hasAuthorship W2738559968A5060303060 @default.
• W2738559968 hasAuthorship W2738559968A5074258039 @default.
• W2738559968 hasAuthorship W2738559968A5089497961 @default.
• W2738559968 hasBestOaLocation W27385599681 @default.
• W2738559968 hasConcept C126322002 @default.
• W2738559968 hasConcept C141071460 @default.
• W2738559968 hasConcept C141105273 @default.
• W2738559968 hasConcept C159654299 @default.
• W2738559968 hasConcept C187212893 @default.
• W2738559968 hasConcept C197934379 @default.
• W2738559968 hasConcept C203014093 @default.
• W2738559968 hasConcept C2776042228 @default.
• W2738559968 hasConcept C2777995640 @default.
• W2738559968 hasConcept C2778375690 @default.
• W2738559968 hasConcept C2778564945 @default.
• W2738559968 hasConcept C2778715236 @default.
• W2738559968 hasConcept C71924100 @default.
• W2738559968 hasConceptScore W2738559968C126322002 @default.
• W2738559968 hasConceptScore W2738559968C141071460 @default.
• W2738559968 hasConceptScore W2738559968C141105273 @default.
• W2738559968 hasConceptScore W2738559968C159654299 @default.
• W2738559968 hasConceptScore W2738559968C187212893 @default.
• W2738559968 hasConceptScore W2738559968C197934379 @default.
• W2738559968 hasConceptScore W2738559968C203014093 @default.
• W2738559968 hasConceptScore W2738559968C2776042228 @default.
• W2738559968 hasConceptScore W2738559968C2777995640 @default.
• W2738559968 hasConceptScore W2738559968C2778375690 @default.
• W2738559968 hasConceptScore W2738559968C2778564945 @default.

• next